Damon Inc. Reports No Revenue, Posts $14 Million Goodwill Impairment for Fiscal 2025

Reuters
2025/09/30
<a href="https://laohu8.com/S/DMNID">Damon Inc.</a> Reports No Revenue, Posts $14 Million Goodwill Impairment for Fiscal 2025

For the year ended June 30, 2025, the scientific software products and services segment reported revenue of $222,736, compared to no revenue in the prior period. Cost of revenue for this segment was $107,394, resulting in a gross profit of $115,342. Operating expenses for the year ended June 30, 2025, included research and development costs of $3.05 million, general and administrative expenses of $8.43 million, sales and marketing expenses of $559,190, transaction costs of $4.95 million, and depreciation of $210,828. Impairment charges totaled $14.12 million for the period. There were no revenues or cost of revenue reported for the electric motorcycles segment for the year ended June 30, 2025. The company identified indicators of impairment for goodwill and intangible assets related to the scientific software products and services segment, leading to a quantitative impairment test and subsequent charges.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Damon Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-093259), on September 30, 2025, and is solely responsible for the information contained therein.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10